There are 1105 resources available
309P - Risk stratification of advanced urothelial carcinoma in the era of cancer immunotherapy
Presenter: Go Kaneko
Session: Poster Display session
Resources:
Abstract
310P - Real-world observation of treatment patterns and long-term clinical outcome in non-muscle invasive bladder cancer (NMIBC)
Presenter: Makito Miyake
Session: Poster Display session
Resources:
Abstract
311P - The value of blood oxygenation level-dependent (BOLD) MR in differentiation of fumarate hydratase-deficient renal cell carcinoma and high-grade clear cell renal cell carcinoma
Presenter: Fengnian Zhao
Session: Poster Display session
Resources:
Abstract
312P - Efficacy and safety of tislelizumab plus axitinib in the treatment of locally advanced clear cell renal cell carcinoma: A single center clinical study
Presenter: Changwei Ji
Session: Poster Display session
Resources:
Abstract
313P - Surveillance of patients with complete response following first-line chemotherapy for germ cell tumors (GCTs)
Presenter: Saengrawee Arunothai
Session: Poster Display session
Resources:
Abstract
314P - Effectiveness of tislelizumab combined with chemotherapy for high recurrence risk patients with upper tract urothelial carcinoma after radical nephroureterectomy
Presenter: jingwen Zhang
Session: Poster Display session
Resources:
Abstract
315P - Clinical characterization and outcomes of patients with PAX8 positive cancer of unknown primary: A distinct immunophenotypic subset
Presenter: Joelle Allam
Session: Poster Display session
Resources:
Abstract
316P - Deciphering the poor prognostic signature of SLC7A5 in clear cell renal cell carcinoma and its impact on tumor immune microenvironment
Presenter: Rami Jadallah
Session: Poster Display session
Resources:
Abstract
317P - Upper tract urothelial carcinoma with TP53 mutation treated by platinum-based neoadjuvant chemotherapy may induce tumor infiltrating lymphocytes in the tumor microenvironment
Presenter: Daiki Ikarashi
Session: Poster Display session
Resources:
Abstract
318P - RA-VEIL, VEIL or O-ILND which should be used for inguinal lymphadenectomy
Presenter: Hongjun Yin
Session: Poster Display session
Resources:
Abstract